1. How Will Aducanumab Approval Impact AD Research?

   • Michael W. Weiner
   • P. S. Aisen
   • Alzheimer’s Disease Neuroimaging Initiative (ADNI)

   Editorial 22 July 2021 Pages: 391 - 392

2. Consequences of the FDA Decision on Aducanumab for Patient Care and Research

   • Rachelle Doody

   Editorial 20 July 2021 Pages: 393 - 395

3. Impact of Aduhelm Approval on Care and Policy

   • B. Kallmyer
   • M. Daven
   • Maria C. Carrillo

   Editorial 20 July 2021 Pages: 396 - 397

4. Aducanumab: Appropriate Use Recommendations

   • Jeffrey Cummings
   • P. Aisen
   • M. Weiner

   Special Article Open access 20 July 2021 Pages: 398 - 410

   

5. The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice

   • Serge Gauthier
   • P. Rosa-Neto

   Commentary 20 July 2021 Pages: 411 - 411

6. Aducanumab: Appropriate Use Recommendations

   • Philip Scheltens
   • E. G. B. Vijverberg

   Editorial 20 July 2021 Pages: 412 - 413

7. Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

   • S. L. Lowe
   • C. Duggan Evans
   • AACD Investigators

   Original Research Open access 21 September 2021 Pages: 414 - 424

   

8. The Cost-Effectiveness of Three Prevention Strategies in Alzheimer’s Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)

   • Nadège Costa
   • M. Mounié
   • MAPT/DSA Group

   Original Research Open access 02 August 2021 Pages: 425 - 435

   

9. The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults

   • Elizabeth W. Katzman
   • S. J. Nielsen

   Brief Reports 11 June 2021 Pages: 436 - 441

10. Early-Onset Subgroup of Type 2 Diabetes and Risk of Dementia, Alzheimer’s disease and Stroke: A Cohort Study

    • K. Wang
    • Hong Liu

    Original Research 24 June 2021 Pages: 442 - 447

    

11. A UK-Wide Study Employing Natural Language Processing to Determine What Matters to People about Brain Health to Improve Drug Development: The Electronic Person-Specific Outcome Measure (ePSOM) Programme

    • Stina Saunders
    • G. Muniz-Terrera
    • S. Luz

    Original Research Open access 09 June 2021 Pages: 448 - 456

    

12. A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans

    • Justin T. McDaniel
    • R. J. McDermott
    • T. Schneider

    Original Research 04 June 2021 Pages: 457 - 461

    

13. Alzheimer’s Disease Research in Japan: A Short History, Current Status and Future Perspectives toward Prevention

    • Takeshi Iwatsubo
    • Y. Niimi
    • H. Akiyama

    Editorial 30 June 2021 Pages: 462 - 464

14. The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial

    • T. Sugimoto
    • Takashi Sakurai
    • J-MINT investigators

    Original Research 09 June 2021 Pages: 465 - 476

    

15. Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer’s Disease Risk Factors

    • Tatsuo Mano
    • K. Sato
    • Japanese Alzheimer’s Disease Neuroimaging Initiative

    Original Research 09 June 2021 Pages: 477 - 482

    

16. Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease

    • T. Ochiai
    • T. Nagayama
    • Takeshi Iwatsubo

    Original Research 17 June 2021 Pages: 483 - 494

    

17. A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer’s Disease

    • Michio Senda
    • K. Ishii
    • H. Shimada

    Original Research 30 June 2021 Pages: 495 - 502

    

18. Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer’s Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer’s Disease Clinical Studies

    • K. Sato
    • T. Mano
    • The A4 Study Team

    Original Research 02 August 2021 Pages: 503 - 512

    

19. Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force

    • Jeffrey Kaye
    • P. Aisen
    • the EU/US CTAD Task Force

    CTAD Task Force Paper Open access 28 June 2021 Pages: 513 - 519

    

20. Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review

    • I. Yunusa
    • N. Rashid
    • Krithika Rajagopalan

    Original Research Open access 06 August 2021 Pages: 520 - 533

    

21. Immunotherapy for Alzheimer’s Disease: Current Scenario and Future Perspectives

    • M. B. Usman
    • S. Bhardwaj
    • Niraj Kumar Jha

    Reviews 15 September 2021 Pages: 534 - 551

    

22. Childhood Secondhand Smoke Exposure and Risk of Dementia in Adulthood

    • Tomoyuki Kawada

    Letter to the Editor 13 September 2021 Pages: 552 - 552